Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuki Haga

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
International Journal of Medical Sciences|November 7, 2019
Superinfection of hepatitis A virus in hepatocytes infected with hepatitis B virusNan Nwe Win, Tatsuo Kanda, Masahiro Ogawa, et al.
Oncotarget|February 14, 2018
Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literatureYuki Haga, Tatsuo Kanda, Shin Yasui, et al.
Oncotarget|April 18, 2018
Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse eventsTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
Oncotarget|March 17, 2018
Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitisTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
International Journal of Molecular Sciences|April 26, 2017
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A InhibitorsTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
Environmental Science and Pollution Research International|December 19, 2012
Polychlorinated biphenyl (118) activates osteoclasts and induces bone resorption in goldfishKoji Yachiguchi, Noriko Matsumoto, Yuki Haga, et al.
Liver Cancer|October 1, 2020
Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular CarcinomaSusumu Maruta, Sadahisa Ogasawara, Yoshihiko Ooka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2023
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH StudyKazufumi Kobayashi, Sadahisa Ogasawara, Susumu Maruta, et al.
Investigational New Drugs|June 8, 2019
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in JapanSadahisa Ogasawara, Yoshihiko Ooka, Norio Itokawa, et al.
BMC Gastroenterology|April 2, 2023
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practiceSae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
International Journal of Medical Sciences|November 7, 2019
Superinfection of hepatitis A virus in hepatocytes infected with hepatitis B virusNan Nwe Win, Tatsuo Kanda, Masahiro Ogawa, et al.
Oncotarget|February 14, 2018
Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literatureYuki Haga, Tatsuo Kanda, Shin Yasui, et al.
Oncotarget|April 18, 2018
Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse eventsTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
Oncotarget|March 17, 2018
Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitisTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
International Journal of Molecular Sciences|April 26, 2017
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A InhibitorsTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
Environmental Science and Pollution Research International|December 19, 2012
Polychlorinated biphenyl (118) activates osteoclasts and induces bone resorption in goldfishKoji Yachiguchi, Noriko Matsumoto, Yuki Haga, et al.
Liver Cancer|October 1, 2020
Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular CarcinomaSusumu Maruta, Sadahisa Ogasawara, Yoshihiko Ooka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2023
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH StudyKazufumi Kobayashi, Sadahisa Ogasawara, Susumu Maruta, et al.
Investigational New Drugs|June 8, 2019
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in JapanSadahisa Ogasawara, Yoshihiko Ooka, Norio Itokawa, et al.
BMC Gastroenterology|April 2, 2023
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practiceSae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, et al.
Pageof 8